Precision for Medicine - Atopic Dermatitis

  • Study Sponsor and Protocol Number: 
    Precision for Medicine - DRM-05
  • Specialty:
    Dermatology/Internal Medicine
  • Type:
    Biospecimen
  • Inclusion:
    Age 18 and up
    Diagnosed with any stage of atopic dermatitis
    Scheduled to begin Nemolizumab (Nemluvio) for the first time
  • Exclusion:
    Historic use of Nemolizumab
    • Use of any JAK inhibitor in the last 30 days